Results showed that subjects taking the probiotic formulation experienced a significantly larger reduction in LDL cholesterol and total cholesterol after 12 weeks, compared to placebo.
Photo © AdobeStock.com/Маргарита Медведева
Kaneka Probiotics has announced the publication of a study1 demonstrating the effects of its Cardio Probiotic on serum cholesterol levels. In the study, 91 subjects with a median age of 63.5 and untreated LDL cholesterol greater than 160 mg/dL were randomized to receive either placebo of the Cardio Probiotic, once daily for 12 weeks. The Cardio Probiotic consists of three strains of Lactobacillus plantarum (L. plantarum KABP -011, -012, and -013).
Results showed that subjects taking the probiotic formulation experienced a significantly larger reduction in LDL cholesterol and total cholesterol after 12 weeks, compared to placebo. These effects were also more pronounced in subjects with higher LDL cholesterol levels at baseline.
“Our Cardio strains are very potent producers of Bile Salt Hydrolase enzyme, which is one of the key mechanisms mediating cholesterol decline,” explained Mike Kolifrath, vice president, sales and marketing of the Probiotics Division at Kaneka, in a press release. “This is not a trait shared by all probiotics, so we are confident that innovative brands will incorporate Cardio into their cardiovascular formulations.”
Reference
Cracking the code: Advancements in calcium absorption and nutritional understanding
July 23rd 2024Recent research conducted by ILSI U.S. and Canada – a global, nonprofit federation dedicated to advancing precompetitive research in the food, nutrition and health realms – and partially funded by Balchem, has shed light on how to improve predictions of Ca bioavailability across different food matrices.
Recent animal study finds that Lysoveta may help reduce neonatal brain injury
July 17th 2024A recent animal study found that lysophosphatidylcholine (LPC)-bound omega-3 long-chain polyunsaturated fatty acids (LCPUFAs), marketed as Lysoveta by Aker BioMarine, protected against neonatal hypoxic-ischemic (HI) brain injury in mice.